Concentrated originally on just 4 companies - GSK, Merck & Co., Inc., Pfizer and Sanofi – representing approximately 80% of world vaccine revenue (est. $ 30 billion back in 2016), the vaccine market remains complex, engaged, collaborative and competitive
The 'Big Pharma' leadership has been upended by key Covid-19 vaccine manufacturers, BioNTech (in partnership with industry leader Pfizer) and Moderna
Both firms put high hopes in mRNA vaccines going forward, to treat melanoma among other forms of cancer (BioNTech) and targeting tumors and cardiovascular illness (Moderna in a partnership with AstraZeneca)
Revenue expectations have fluctuated widely with the launch of Covid vaccines (generating as much as $57 billion for Pfizer alone in 2022 - 60% of th firm's total year revenue) - expectations of all Covid vaccine manufacturers are down by 50% in 2023
With support of the Gavi Alliance , vaccinations in poor countries reach more than 500 million children since 2000, preventing an estimated 7 million deaths
Heathcare companies partnerships with the Alliance are collaborative - for GSK and Merck, price strategies are sensitive to each country’s ability to pay and, in the case of Sanofi, registration of its relevant vaccines benefits 30-50% of low- and lower-middle-income countries
For in-depth information, visit Gavi Alliance